Escalier Biosciences is developing both topical and oral RORγt inverse agonists for the treatment of a broad spectrum of psoriasis patients – from the underserved mild-to-moderate patients that would benefit from a safe and effective topical RORγt therapeutic to the more moderate-to-severe patients that would benefit from a safe and effective oral RORγt drug in lieu of injectable biologic therapies targeting IL-17 and IL-23.

Biotechnology

Education

Escalier Biosciences

Teams at Escalier Biosciences

Advisory Board

Leadership Team